Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01091649 · ClinicalTrials.gov registry record · Phase 1

Study in Healthy Adults to Evaluate the Bioavailability of Two Test Tablet Formulations of ABT-450

A Phase 1 study of Healthy, sponsored by Abbott.

Completed
Registry status
Phase 1
Development phase
40
Enrollment target
1
Study location

NCT01091649 is a Phase 1 study of Healthy that has completed, run by Abbott. The registered enrollment target is 40 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01091649, a Phase 1 study of Healthy, has completed, sponsored by Abbott.

COMPLETED
Registry status
Phase 1
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

The objective of this study is to assess the relative bioavailability of two test tablet formulations of ABT-450 as compared to the ABT-450 hard gelatin capsule formulation as a reference.

Conditions Studied

Interventions

  • DRUG ritonavir
  • DRUG ABT-450

Study Locations (1)

Illinois

  • Site Reference ID/Investigator# 27781 - Waukegan

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2010-02
Est. Completion 2010-04
Phase Phase 1

Sponsor

Abbott

181 total trials

What the Registry Record Tells You About NCT01091649

The ClinicalTrials.gov registry entry for NCT01091649 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (94% lower). The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which ritonavir is the first listed.

NCT01091649 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT01091649 about?

NCT01091649 is a clinical study titled "Study in Healthy Adults to Evaluate the Bioavailability of Two Test Tablet Formulations of ABT-450". The objective of this study is to assess the relative bioavailability of two test tablet formulations of ABT-450 as compared to the ABT-450 hard gelatin capsule formulation as a reference.

What is the current status of trial NCT01091649?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2010-02. Estimated completion is 2010-04.

What conditions does trial NCT01091649 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT01091649?

The interventions under investigation include: ritonavir (DRUG), ABT-450 (DRUG).

Who is sponsoring clinical trial NCT01091649?

This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01091649 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.